Zendesk ZEN 深 沪
等待开盘 09-20 09:30:00 美东时间
77.48
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 77.48
- 总市值 96.08亿
- 52周最高 130.83
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 54.16
- 委 比 0.00%
- 总股本 1.24亿
- 历史最高 166.60
- 量 比 0
- 振 幅 0.00%
- 历史最低 11.06
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多大芯片，一夜生变
据昨晚的新闻报道，NVIDIA将以每股 23.28 美元的价格向英特尔普通股投资 50 亿美元，双方也将合作开发多代定制数据中心和 PC 产品，以加速超大规模...
09-19 09:50
Zentek Has Completed The First In Vivo Tests Of The Lead Candidate Countermeasure For Seasonal Influenza; Was Awarded ~$1.1M Through The Government Of Canada's Innovative Solutions Canada
Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), is pleased to announce that it has completed the first in vivo tests of the lead candidate countermeasure for seasonal influenza (H1N1) as part of the
09-18 20:28
ZENVIA welcomes Piero Rosatelli as CFO & IRO
SÃO PAULO, Sept. 15, 2025 /PRNewswire/ -- Zenvia Inc. (NASDAQ: ZENV), the leading cloud-based CX solution in Latin America empowering companies to craft personal, engaging and fluid experien...
09-16 04:30
Zenith Energy Challenges ICC-2 Arbitration Award in Swiss Court
The latest update is out from Zenith Energy ( ($GB:ZEN) ). Zenith Energy Ltd. i...
09-15 13:34
ZENVIA Reports Q2 2025 Results
Transition to Zenvia Customer Cloud moving on as expected, with revenues from these services up 23% YoY CPaaS revenues still fueling top line Continued strict expense control SÃO PAULO, Se...
09-11 06:30
征拓首次推出电动货运自行车概念
太阳能创新企业征拓（Zendure）宣布拓展其智能ZEN+家庭能源管理系统（HEMS），新增精准负载控制、数据驱动型优化能源管理及语音助手等功能。ZEN+家庭生...
09-05 15:15
Zentek’s Albany Graphite Corp. Secures $500,000 Grant for Purification Project
Zentek ( ($TSE:ZEN) ) just unveiled an update. Albany Graphite Corp., a subsidi...
09-02 20:44
Reported Friday, Genentech And Alnylam Initiate ZENITH Phase III Trial Evaluating Zilebesiran in 11,000 Patients With Uncontrolled Hypertension
– Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 –– In the Phase II KARDIA-3 study, presented today as a late breaker at
09-02 16:09
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
Zenas BioPharma and Royalty Pharma have announced a $300 million funding partnership for the development and commercialization of obexelimab, a potential treatment for IgG4-Related Disease. This includes an initial $75 million payment and further installments tied to Phase 3 trial results, FDA approval, and potential indications in other autoimmune diseases like lupus and multiple sclerosis. Obexelimab is a bifunctional monoclonal antibody design...
09-02 11:05
医疗板块回暖+中报营收利润双高增，归创通桥（2190.HK）凭什么领跑创新械企？
2025年以来，沉寂已久的港股医药行业迎来强势反弹。富途显示，今年恒生医疗保健指数累计涨幅已突破100%，不仅如同一记强心针点燃市场热情，更引发市场对行业走势的...
08-27 11:40
